Jason Najum's Blog

Psychedelic medicine therapy. Trying to fit the subtleties of human psychology and the incomprehensible experience of multi-dimensional ego obliteration into a scalable and commercially-viable service.

The psychedelic medicine sector provides some unique value investment opportunities. Here’s why Cybin could be the best value bet among this group of biotech pioneers.

The psychedelic medicine sector provides some unique value investment opportunities. Here’s why Cybin could be the best value bet among this group of biotech pioneers.

The FDA has rejected MDMA therapy, but this setback could potentially benefit other psychedelic stocks.

A look at the FDA's upcoming decision on MDMA therapy and how it might affect other psychedelic stocks.

As we close out the year, let’s take a look back at some of the more important milestones in the psychedelic medicine space. From legalization to clinical trials, the psychedelic sector continued to make steady progress on all fronts.

As we close out the year, let’s take a look back at some of the more important milestones in the psychedelic medicine space. From legalization to clinical trials, the psychedelic sector continued to make steady progress on all fronts.

The psychedelic medicine industry continues to get attention and gain credibility in the investment world.

Microdose's editor Jason Najum shares his personal experience with ketamine psychedelic therapy.

Microdose's Managing Editor sits down with the CEO of Cybin to discuss their innovative approach to treating neurological and psychiatric conditions using psilocybin-assisted psychotherapy.